Validation and clinical application of dried blood spot assay for quantitative assessment of edoxaban in healthy adults

Bioanalysis. 2020 Mar;12(6):393-407. doi: 10.4155/bio-2019-0180.

Abstract

Aim: Dried blood spot (DBS) is a sampling approach that offers several advantages over plasma and whole blood (WB) sampling, but several factors, such as hematocrit and temperature, can adversely affect quantitation. Methodology & results: In an open-label, three-way crossover study in healthy subjects, we explored the correlation between DBS, WB and plasma samples, and between DBS samples from finger-prick and venipuncture blood for measuring edoxaban and its metabolite M-4 using LC-MS/MS. The methods were validated comprehensively. The incurred sample reanalysis experiments demonstrated quantitation reproducibility in all three matrices. Overall, there was a good correlation (near perfect concordance for edoxaban) among plasma, WB and DBS measurements. M-4 concentrations in DBS and WB were lower than in plasma. Conclusion: These results indicate using DBS may be used as an alternative methodology to measure edoxaban pharmacokinetics.

Keywords: bioanalytical method validation; concordance; dried blood spot; edoxaban; finger prick; incurred sample analysis.

MeSH terms

  • Cross-Over Studies
  • Dried Blood Spot Testing / methods*
  • Factor Xa Inhibitors / pharmacology
  • Factor Xa Inhibitors / therapeutic use*
  • Healthy Volunteers
  • Humans
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Reproducibility of Results
  • Thiazoles / pharmacology
  • Thiazoles / therapeutic use*

Substances

  • Factor Xa Inhibitors
  • Pyridines
  • Thiazoles
  • edoxaban